Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05766683 · ClinicalTrials.gov registry record · Phase 1
Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines
A Phase 1 study of Glabellar Frown Lines, sponsored by Henry Ford Health System.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05766683 is a Phase 1 study of Glabellar Frown Lines that is active but no longer recruiting, run by Henry Ford Health System. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05766683, a Phase 1 study of Glabellar Frown Lines, is active but no longer recruiting, sponsored by Henry Ford Health System.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines? STUDY AIM * Primary objective: Compare the efficacy of onabotulinumtoxinA neurotoxin injected at the depth of 2mm vs 4mm for the improvement of glabellar lines * Secondary objective: Determine any adverse effects of onabotulinumtoxinA neurotoxin injected at the depth of 2mm vs 4mm RATIONALE FOR THE PROJECT: Although the use of BoTN for treatment of glabellar lines has long been established as safe and effective, the optimal depth of injection has not been established. Our project hopes to establish the optimal depth of injection for onabotulinumtoxinA neurotoxin for maximal improvement of glabellar lines with minimal adverse effects
Conditions Studied
Interventions
- DRUG onabotulinumtoxinA at a depth of 2mm
- DRUG onabotulinumtoxinA at a depth of 4mm
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05766683
The ClinicalTrials.gov registry entry for NCT05766683 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glabellar Frown Lines appearing as the primary indexed condition, and to 2 interventions - of which onabotulinumtoxinA at a depth of 2mm is the first listed.
NCT05766683 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05766683 about?
NCT05766683 is a clinical study titled "Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines". STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines? STUDY AIM * Primary objective: Compare the efficacy of onabotulinumtoxinA neurotoxin injected at the depth of 2mm vs 4mm fo...
What is the current status of trial NCT05766683?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-03-14. Estimated completion is 2026-12.
What conditions does trial NCT05766683 study?
This clinical trial studies the following conditions: Glabellar Frown Lines.
What interventions are being tested in trial NCT05766683?
The interventions under investigation include: onabotulinumtoxinA at a depth of 2mm (DRUG), onabotulinumtoxinA at a depth of 4mm (DRUG).
Who is sponsoring clinical trial NCT05766683?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05766683 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glabellar Frown Lines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.